Revolutionary Boost: Advanced NanoTherapies (ANT) Clinches $4M Game-Changing Investment to Fast-Track SirPlux Duo’s Battle Against Coronary Artery Disease!

“Revolution Unleashed: ANT Triumphs with 10 Brave Hearts Leading the Charge in Breakthrough Trial!”

LOS GATOS, Calif., Aug. 22, 2023 /PRNewswire/ — Brace yourselves for a seismic shift in the medical landscape as Advanced NanoTherapies Inc. (ANT), the architects of innovation in vascular disease treatment, declare a $4M Series A extension as a battle cry. A mysterious ally from the medical realm has joined forces with ANT, ensuring that their vision reaches new heights.

But the excitement doesn’t end there. ANT has wielded its pioneering prowess to conquer uncharted territories. In a stunning show of triumph, the curtains rise on the ADVANCE-DCB first-in-human (FIH) trial, where the stage is set for SirPlux Duo DCB to prove its mettle against the formidable foe – de novo coronary artery disease (CAD).

Feel the pulse of innovation as Marwan Berrada, the virtuoso behind ANT’s brilliance, declares, “Today, two stars shine brightly for ANT and SirPlux Duo DCB.” With strategic investment as a guiding light, the path to U.S. IDE approval for SirPlux Duo DCB is now a blazing trail. Marwan’s gratitude extends to the ANT dream team and scientific advisory board, the unsung heroes who have woven this success story.

Enter the SirPlux Duo DCB, a symphony of science fusing sirolimus and paclitaxel into a marvel that redefines therapy. Picture this: stent-like efficacy with zero implants left behind. It’s a new era where cell growth is tamed by a dual-drug dance, setting a standard that eclipses the competition. ANT’s ingenuity turns particles into powerful protectors, delivering the magic potion safely and sustainably.

From the frontlines, Investigator Rishi Puri MD, PhD of the Cleveland Clinic’s Heart, Vascular and Thoracic Institute, exclaims, “ANT’s technology is my ticket to revolutionize coronary care.” The promise of extended, implant-free therapy fuels his enthusiasm.

In distant Auckland, Investigator Dr. Jith Somaratne of Auckland City Hospital and The Heart Group joins the chorus, “SirPlux Duo DCB heralds a new dawn in coronary interventions.” With the fusion of mighty drugs in a nanoparticle embrace, he envisions a realm of fewer setbacks and maintained pathways.

Mark your calendars for 2024, as the curtains part once more. ANT promises a visual symphony as they unveil the angiographic masterpiece, the fruit of their ADVANCE-DCB FIH trial. This isn’t just science; it’s a revolution painted in pulsating hues of innovation.

About Advanced NanoTherapies

Prepare to step into a realm where science and healing intertwine, orchestrated by the virtuosos at Advanced NanoTherapies, Inc. This is no ordinary medical device company – this is a haven of innovation, a forge of possibilities where nanoparticle technology emerges as the hero in the realm of drug delivery.

Envision a future where cardiovascular treatments dance on the edge of invasiveness. Advanced NanoTherapies has cracked the code to offer a safer haven for those battling coronary artery disease (CAD) and peripheral artery disease (PAD). It’s a revolution wrapped in the promise of healing, where the SirPlux Duo DCB takes center stage as a trailblazing therapy for a new era. Step into the spotlight of medical evolution – this is where tomorrow’s treatments are crafted today.

Leave a Comment